Why Clinical Modulation of Efflux Transport at the Human Blood–Brain Barrier Is Unlikely: The ITC Evidence-Based Position
Year: 2013
Type: review
DOI: 10.1038/clpt.2013.34
Institutions: Abbott (United States), GlaxoSmithKline (United States), Theravance Biopharma (United States), Pfizer (United States), United States Food and Drug Administration, Center for Drug Evaluation and Research, Genentech, Texas Tech University Health Sciences Center, Eli Lilly (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2049517140
